

Miguel Angel Diaz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/136876/publications.pdf>

Version: 2024-02-01

196
papers

4,734
citations

134610

34
h-index

190340

53
g-index

211
all docs

211
docs citations

211
times ranked

6087
citing authors

#	ARTICLE	IF	CITATIONS
1	HEV infection in stem cell transplant recipientsâ€”retrospective study of EBMT Infectious Diseases Working Party. <i>Bone Marrow Transplantation</i> , 2022, 57, 167-175.	1.3	6
2	Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 187.e1-187.e10.	0.6	3
3	The Impact of Pre-Apheresis Health Related Quality of Life on Peripheral Blood Progenitor Cell Yield and Donor's Health and Outcome: Secondary Analysis of Patient-Reported Outcome Data from the RDSafe and BMT CTN 0201 Clinical Trials. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 603.e1-603.e7.	0.6	4
4	Association of Chronic Graft-versus-Host Disease with Late Effects following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic Malignancy. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 712.e1-712.e8.	0.6	3
5	Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 68.e1-68.e9.	0.6	15
6	African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. <i>Cancer</i> , 2021, 127, 82-92.	2.0	15
7	Plerixaforâ€”based mobilization in pediatric healthy donors with unfavorable donor/recipient body weight ratio resulted in a better <scp>CD34</scp> ⁺ collection yield: A retrospective analysis. <i>Journal of Clinical Apheresis</i> , 2021, 36, 78-86.	0.7	3
8	Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States. <i>Cancer</i> , 2021, 127, 609-618.	2.0	12
9	Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis. <i>Blood</i> , 2021, 137, 556-568.	0.6	34
10	Defibrotide in hematopoietic stem cell transplantation: A multicenter survey study of the Spanish Hematopoietic Stem Cell Transplantation Group (GETH). <i>European Journal of Haematology</i> , 2021, 106, 842-850.	1.1	2
11	Natural killer cell alloreactivity in HLA-haploidentical hematopoietic transplantation: a study on behalf of the CTIWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 1900-1907.	1.3	18
12	Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. <i>Blood</i> , 2021, 137, 3291-3305.	0.6	85
13	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2108-2117.	1.3	6
14	â€œExâ€”vivoâ€”Tâ€”cell depletion in allogeneic hematopoietic stem cell transplantation: New clinical approaches for old challenges. <i>European Journal of Haematology</i> , 2021, 107, 38-47.	1.1	5
15	Graft failure after â€œex-vivoâ€”T-cell depleted haploidentical transplantation in pediatric patients with high-risk hematological malignancies. A risk factors and outcomes analysis. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-8.	0.6	3
16	Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 921.e1-921.e10.	0.6	11
17	Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 993.e1-993.e8.	0.6	4
18	Comparison of clinical outcomes between unrelated single umbilical cord blood and â€œex-vivoâ€”T-cell depleted haploidentical transplantation in children with hematological malignancies. <i>World Journal of Pediatrics</i> , 2021, 17, 609-618.	0.8	2

#	ARTICLE	IF	CITATIONS
19	Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) As Consolidation Following CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for Treatment of Relapsed Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2021, 138, 3880-3880.	0.6	4
20	Haploidentical transplantation in high-risk pediatric leukemia: A retrospective comparative analysis on behalf of the Spanish working Group for bone marrow transplantation in children (GETMON) and the Spanish Grupo for hematopoietic transplantation (GETH). <i>American Journal of Hematology</i> , 2020, 95, 28-37.	2.0	34
21	Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 553-561.	2.0	13
22	Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant. <i>JAMA Network Open</i> , 2020, 3, e1918668.	2.8	40
23	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020, 4, 3180-3190.	2.5	18
24	A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2139-2146.	2.0	14
25	Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. <i>Journal of Clinical Oncology</i> , 2020, 38, 2062-2076.	0.8	36
26	Impact of autologous blood transfusion after bone marrow harvest on unrelated donor's health and outcome: a CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2020, 55, 2121-2131.	1.3	7
27	Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases. <i>Blood Advances</i> , 2020, 4, 2084-2094.	2.5	14
28	Survival following allogeneic transplant in patients with myelofibrosis. <i>Blood Advances</i> , 2020, 4, 1965-1973.	2.5	63
29	The Impact of Donor Type on Outcomes and Cost of Allogeneic Hematopoietic Cell Transplantation for Pediatric Leukemia: A Merged Center for International Blood and Marrow Transplant Research and Pediatric Health Information System Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1747-1756.	2.0	7
30	Collection of Peripheral Blood Progenitor Cells in 1 Day Is Associated with Decreased Donor Toxicity Compared to 2 Days in Unrelated Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1210-1217.	2.0	4
31	COVID-19 in pediatric hematopoietic stem cell transplantation: The experience of Spanish Group of Transplant (GETMON/GETH). <i>Pediatric Blood and Cancer</i> , 2020, 67, e28514.	0.8	57
32	Outcome of patients with Fanconi anemia developing myelodysplasia and acute leukemia who received allogeneic hematopoietic stem cell transplantation: A retrospective analysis on behalf of <sc>EBMT</sc> group. <i>American Journal of Hematology</i> , 2020, 95, 809-816.	2.0	30
33	Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. <i>Leukemia</i> , 2020, 34, 3338-3347.	3.3	27
34	Weighty choices: selecting optimal G-CSF doses for stem cell mobilization to optimize yield. <i>Blood Advances</i> , 2020, 4, 706-716.	2.5	11
35	Transplantation for Congenital Sideroblastic Anaemia Is Feasible and Offers Outcomes Comparable to Other Transfusion Dependent Anaemias. a Joint Retrospective Study of the Paediatric Diseases and Severe Aplastic Anaemia Working Parties (PDWP/SAAWP) of EBMT. <i>Blood</i> , 2020, 136, 45-47.	0.6	0
36	Ruxolitinib treatment for steroid refractory acute and chronic graft vs host disease in children: Clinical and immunological results. <i>American Journal of Hematology</i> , 2019, 94, 319-326.	2.0	59

#	ARTICLE	IF	CITATIONS
37	Kinetics and Risk Factors of Relapse after Allogeneic Stem Cell Transplantation in Children with Leukemia: A Long-Term Follow-Up Single-Center Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 100-106.	2.0	11
38	Allogeneic stem cell transplantation for acquired pure red cell aplasia. <i>American Journal of Hematology</i> , 2019, 94, E294-E296.	2.0	9
39	Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study. <i>Transplant Infectious Disease</i> , 2019, 21, e13145.	0.7	22
40	Hashimoto encephalopathy as manifestation of central nervous system chronic graft-versus-host disease after hematopoietic stem cell transplantation. <i>Pediatric Blood and Cancer</i> , 2019, 66, e28008.	0.8	2
41	Comparison of High Doses of Total Body Irradiation in Myeloablative Conditioning before Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2398-2407.	2.0	21
42	The Concentration of Total Nucleated Cells in Harvested Bone Marrow for Transplantation Has Decreased over Time. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1325-1330.	2.0	13
43	Virus detection in the cerebrospinal fluid of hematopoietic stem cell transplant recipients is associated with poor patient outcomes: a CIBMTR contemporary longitudinal study. <i>Bone Marrow Transplantation</i> , 2019, 54, 1354-1360.	1.3	19
44	Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1875-1883.	2.0	14
45	Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1099-1106.	2.0	12
46	CD45 RA Depletion As an Allogeneic Hematopoietic Transplantation Platform in Children from HLA-Identical Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S205-S206.	2.0	0
47	Ruxolitinib Treatment for Steroid Refractory ACUTE and Chronic GRAFT Versus Host Disease in Children: Clinical and Immunological Results. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S257-S258.	2.0	1
48	GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. <i>Blood Advances</i> , 2019, 3, 1441-1449.	2.5	12
49	The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. <i>Blood Advances</i> , 2019, 3, 670-680.	2.5	71
50	Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1. <i>Blood Advances</i> , 2019, 3, 2525-2536.	2.5	13
51	Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. <i>Blood Advances</i> , 2019, 3, 3123-3131.	2.5	37
52	Haploidentical Stem Cell Transplantation in Children With Hematological Malignancies Using $\hat{I}^{\pm}I^2+$ T-Cell Receptor and CD19+ Cell Depleted Grafts: High CD56dim/CD56bright NK Cell Ratio Early Following Transplantation Is Associated With Lower Relapse Incidence and Better Outcome. <i>Frontiers in Immunology</i> , 2019, 10, 2504.	2.2	13
53	Ocular toxocarasis in a pediatric patient undergoing a bone marrow transplantation. <i>Enfermedades Infecciosas Y Microbiologia Clinica (English Ed)</i> , 2019, 37, 618.	0.2	0
54	Toxoplasmosis and secondary Guillain-Barré associated with ruxolitinib as graft-versus-host disease treatment. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27446.	0.8	6

#	ARTICLE	IF	CITATIONS
55	Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 683-688.	2.0	18
56	Ocular toxocariasis in a pediatric patient undergoing a bone marrow transplantation. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019, 37, 617-618.	0.3	1
57	Outcomes after Second Hematopoietic Cell Transplantation in Children and Young Adults with Relapsed Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 301-306.	2.0	27
58	Autoimmune hemolytic anemia (AIHA) following allogeneic hematopoietic stem cell transplantation (HSCT): A retrospective analysis and a proposal of treatment on behalf of the Grupo Español De Trasplante de Medula Osea en Niños (GETMON) and the Grupo Español de Trasplante Hematopoyetico (GETH). <i>Transfusion Medicine Reviews</i> , 2018, 32, 179-185.	0.9	30
59	Reduced-intensity conditioning haematopoietic stem cell transplantation in genetic diseases: Experience of the Spanish Working Group for Bone Marrow Transplantation in Children. <i>Anales De Pediatría (English Edition)</i> , 2018, 88, 196-203.	0.1	0
60	Neurocysticercosis: An unusual seizure etiology in a hematopoietic stem cell transplanted patient. <i>Pediatric Hematology and Oncology</i> , 2018, 35, 20-22.	0.3	4
61	Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 1036-1049.e5.	1.5	233
62	Low Body Mass Index Is Associated with Increased Risk of Acute GVHD after Umbilical Cord Blood Transplantation in Children and Young Adults with Acute Leukemia: A Study on Behalf of Eurocord and the EBMT Pediatric Disease Working Party. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 799-805.	2.0	22
63	Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1928-1935.	2.0	2
64	Second Hematopoietic Stem Cell Transplantation for Post-Transplantation Relapsed Acute Leukemia in Children: A Retrospective EBMT-PDWP Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1629-1642.	2.0	44
65	Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 478-485.	2.0	31
66	Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34+ Yields Are Less. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 175-184.	2.0	7
67	Outcome of childhood leukaemia survivors and necrosis of the femoral head treated with autologous mesenchymal stem cells. <i>Clinical and Translational Oncology</i> , 2018, 20, 584-590.	1.2	5
68	Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 726-733.	2.0	71
69	Herpes 6 Encephalitis: Clinical and Immunological Characteristics in Pediatric Patients with Leukemia Undergoing Depleted Haploidentical Hematopoietic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S432-S433.	2.0	1
70	Donor KIR Genotype Impacts on Clinical Outcome after T Cell-Depleted HLA Matched Related Allogeneic Transplantation for High-Risk Pediatric Leukemia Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2493-2500.	2.0	20
71	Early and late outcomes after cord blood transplantation for pediatric patients with inherited leukodystrophies. <i>Blood Advances</i> , 2018, 2, 49-60.	2.5	45
72	Outcome of haematopoietic stem cell transplantation in dyskeratosis congenita. <i>British Journal of Haematology</i> , 2018, 183, 110-118.	1.2	53

#	ARTICLE	IF	CITATIONS
73	Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2443-2449.	2.0	11
74	Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation. <i>Cancer</i> , 2017, 123, 1828-1838.	2.0	73
75	Donor age matters in T-cell depleted haploidentical hematopoietic stem cell transplantation in pediatric patients: Faster immune reconstitution using younger donors. <i>Leukemia Research</i> , 2017, 57, 60-64.	0.4	33
76	Personalized Prognostic Risk Score for Long-Term Survival for Children with Acute Leukemia after Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1523-1530.	2.0	13
77	Impact of Higher-Dose Total Body Irradiation Conditioning on Outcome of an Allogeneic Hematopoietic Cell Transplant (HCT) in the Modern Era. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S94-S95.	2.0	0
78	Influence of a Moderate-Intensity Exercise Program on Early NK Cell Immune Recovery in Pediatric Patients After Reduced-Intensity Hematopoietic Stem Cell Transplantation. <i>Integrative Cancer Therapies</i> , 2017, 16, 464-472.	0.8	23
79	Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases. <i>Haematologica</i> , 2017, 102, 1823-1832.	1.7	43
80	Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis. <i>Bone Marrow Transplantation</i> , 2017, 52, 1616-1622.	1.3	44
81	Long-Term Outcomes of Cord Blood Transplantation from an HLA-Identical Sibling for Patients with Bone Marrow Failure Syndromes: A Report From Eurocord, Cord Blood Committee and Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1939-1948.	2.0	19
82	Lipomatous hypertrophy of the interatrial septum, an unusual tachycardia etiology in a hematopoietic stem cell transplanted patient. <i>Pediatric Hematology and Oncology</i> , 2017, 34, 144-145.	0.3	1
83	Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 60-66.	2.0	17
84	Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 269-277.	2.0	19
85	Second Allogeneic Hematopoietic Stem Cell Transplantation for Post-Transplant Relapsed Acute Leukemia in Children - an EBMT PDWP Retrospective Study. <i>Blood</i> , 2017, 130, 912-912.	0.6	0
86	Prognostic factors and outcomes for pediatric patients receiving an haploidentical relative allogeneic transplant using CD3/CD19-depleted grafts. <i>Bone Marrow Transplantation</i> , 2016, 51, 1211-1216.	1.3	29
87	The therapeutic potential of natural killer cells to target medulloblastoma. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 573-576.	1.1	14
88	Significant Improvements in the Practice Patterns of Adult Related Donor Care in US Transplantation Centers. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 520-527.	2.0	14
89	Incidence and severity of crucial late effects after allogeneic HSCT for malignancy under the age of 3 years: TBI is what really matters. <i>Bone Marrow Transplantation</i> , 2016, 51, 1482-1489.	1.3	28
90	Immunomagnetic T Cell Depletion: an Analysis of Variables Affecting Final Cell Yield. <i>Clinical Laboratory</i> , 2016, 62, 1243-1248.	0.2	1

#	ARTICLE	IF	CITATIONS
91	Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2154-2159.	2.0	25
92	Intensive Care Unit Admissions Among Children After Hematopoietic Stem Cell Transplantation. <i>Journal of Pediatric Hematology/Oncology</i> , 2015, 37, 529-535.	0.3	18
93	Arabinoxylan rice bran (MGN-3/Biobran) enhances natural killer cell-mediated cytotoxicity against neuroblastoma <i>in vitro</i> and <i>in vivo</i> . <i>Cytotherapy</i> , 2015, 17, 601-612.	0.3	57
94	Transplantation Outcomes for Children with Hypodiploid Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1273-1277.	2.0	24
95	ATG in paediatric haemopoietic stem cell transplantation. <i>Lancet Haematology</i> , 2015, 2, e178-e179.	2.2	2
96	A phase I/II trial of interleukin-15-stimulated natural killer cell infusion after haplo-identical stem cell transplantation for pediatric refractory solid tumors. <i>Cytotherapy</i> , 2015, 17, 1594-1603.	0.3	69
97	Analysis of the Effect of Race, Socioeconomic Status, and Center Size on Unrelated National Marrow Donor Program Donor Outcomes: Donor Toxicities Are More Common at Low-Volume Bone Marrow Collection Centers. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1830-1838.	2.0	12
98	Outcome of graft failure after allogeneic stem cell transplant: study of 89 patients. <i>Leukemia and Lymphoma</i> , 2015, 56, 656-662.	0.6	32
99	Long-term outcome and prognostic factors of unrelated cord blood transplantation in children with haematological malignancies: a retrospective study using the Spanish Working Party for BMT in Children (GETMON) database. <i>Bone Marrow Transplantation</i> , 2014, 49, 767-772.	1.3	4
100	Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens. <i>Blood</i> , 2014, 123, 1615-1620.	0.6	56
101	Outcome of Transplantation for Acute Myelogenous Leukemia in Children with Down Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 893-897.	2.0	39
102	Defining "poor mobilizer" in pediatric patients who need an autologous peripheral blood progenitor cell transplantation. <i>Cytotherapy</i> , 2013, 15, 132-137.	0.3	14
103	Using Rheopheresis for stem cell Transplantation-Associated Thrombotic Microangiopathy (TA-TMA). <i>Transfusion and Apheresis Science</i> , 2013, 49, 234-237.	0.5	2
104	Response to Rituximab-Based Therapy and Risk Factor Analysis in Epstein Barr Virus-Related Lymphoproliferative Disorder After Hematopoietic Stem Cell Transplant in Children and Adults: A Study From the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. <i>Clinical Infectious Diseases</i> , 2013, 57, 794-802.	2.9	196
105	<i>In vitro</i> Natural Killer Cell Immunotherapy for Medulloblastoma. <i>Frontiers in Oncology</i> , 2013, 3, 94.	1.3	35
106	Allogeneic stem cell transplantation for patients with advanced rhabdomyosarcoma: a retrospective assessment. <i>British Journal of Cancer</i> , 2013, 109, 2523-2532.	2.9	22
107	Very Late Isolated CNS Relapse of Acute Myeloid Leukemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2013, 35, e57-e59.	0.3	3
108	Early evaluation of immune reconstitution following allogeneic CD3/CD19-depleted grafts from alternative donors in childhood acute leukemia. <i>Bone Marrow Transplantation</i> , 2012, 47, 1419-1427.	1.3	37

#	ARTICLE	IF	CITATIONS
109	Once-daily Intravenous Busulfan for 47 Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation. <i>Journal of Pediatric Hematology/Oncology</i> , 2012, 34, 180-183.	0.3	8
110	Varicella zoster central nervous system vasculitis after allogeneic hematopoietic stem cell transplant successfully treated with cyclophosphamide. <i>Transplant Infectious Disease</i> , 2012, 14, E107-10.	0.7	2
111	Natural killer cells can exert a graft-vs-tumor effect in haploidentical stem cell transplantation for pediatric solid tumors. <i>Experimental Hematology</i> , 2012, 40, 882-891.e1.	0.2	43
112	Risk of complications during hematopoietic stem cell collection in pediatric sibling donors: a prospective European Group for Blood and Marrow Transplantation Pediatric Diseases Working Party study. <i>Blood</i> , 2012, 119, 2935-2942.	0.6	82
113	Unrelated cord blood transplantation in adolescent and young adults with hematologic malignancies. <i>Leukemia Research</i> , 2012, 36, 123-124.	0.4	2
114	High-Dose Busulfan and Melphalan as Conditioning Regimen for Autologous Peripheral Blood Progenitor Cell Transplantation in High-Risk Neuroblastoma Patients. <i>Pediatric Hematology and Oncology</i> , 2011, 28, 115-123.	0.3	13
115	High-dose Busulfan and Cyclophosphamide as a Conditioning Regimen for Autologous Peripheral Blood Stem Cell Transplantation in Childhood Non-Hodgkin Lymphoma Patients. <i>Journal of Pediatric Hematology/Oncology</i> , 2011, 33, e89-e91.	0.3	16
116	Higher Doses of CD34+ PBPC are Associated With a Rapid Acquisition of Full Donor Chimerism and Lower Risk of Relapse After Allogeneic Transplantation in Pediatric Patients With Hematological Malignancies. <i>Journal of Pediatric Hematology/Oncology</i> , 2011, 33, 185-189.	0.3	5
117	Pulmonary Glial Heterotopia in a Child Diagnosed With Fanconi Anemia and Epilepsy. <i>Journal of Pediatric Hematology/Oncology</i> , 2011, 33, 462-464.	0.3	3
118	Observational prospective study of viral infections in children undergoing allogeneic hematopoietic cell transplantation: a 3-year GETMON experience. <i>Bone Marrow Transplantation</i> , 2011, 46, 119-124.	1.3	44
119	Allogeneic hematopoietic transplantation using haploidentical donor vs. unrelated cord blood donor in pediatric patients: a single-center retrospective study. <i>European Journal of Haematology</i> , 2011, 87, 46-53.	1.1	29
120	No improvement of survival with reduced- versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients. <i>Annals of Oncology</i> , 2011, 22, 1614-1621.	0.6	42
121	Graft Manipulation and Reduced-intensity Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation From Mismatched Unrelated and Mismatched/Haploidentical Related Donors in Pediatric Leukemia Patients. <i>Journal of Pediatric Hematology/Oncology</i> , 2010, 32, e85-e90.	0.3	34
122	Analysis of Clinical Outcome and Survival in Pediatric Patients Undergoing Extracorporeal Photopheresis for the Treatment of Steroid-refractory GVHD. <i>Journal of Pediatric Hematology/Oncology</i> , 2010, 32, 589-593.	0.3	24
123	Nuclear factor- κ B inducing kinase is required for graft-versus-host disease. <i>Haematologica</i> , 2010, 95, 2111-2118.	1.7	7
124	HIGH-DOSE BUSULFAN AND MELPHALAN AS CONDITIONING REGIMEN FOR AUTOLOGOUS PERIPHERAL BLOOD PROGENITOR CELL TRANSPLANTATION IN HIGH-RISK EWING SARCOMA PATIENTS: A Long-Term Follow-Up Single-Center Study. <i>Pediatric Hematology and Oncology</i> , 2010, 27, 272-282.	0.3	14
125	ALLOGENEIC CORD BLOOD TRANSPLANTATION IN CHILDREN WITH HEMATOLOGICAL MALIGNANCIES: A Long-Term Follow-Up Single-Center Study. <i>Pediatric Hematology and Oncology</i> , 2009, 26, 165-174.	0.3	12
126	Intrathecal liposomal cytarabine in children under 4 years with malignant brain tumors. <i>Journal of Neuro-Oncology</i> , 2009, 95, 65-69.	1.4	22

#	ARTICLE	IF	CITATIONS
127	KIRâ€“HLA receptorâ€“ligand mismatch associated with a graftâ€“versusâ€“tumor effect in haploidentical stem cell transplantation for pediatric metastatic solid tumors. <i>Pediatric Blood and Cancer</i> , 2009, 53, 120-124.	0.8	64
128	Peripheral blood progenitor cell collection adverse events for childhood allogeneic donors: variables related to the collection and safety profile. <i>British Journal of Haematology</i> , 2009, 144, 909-916.	1.2	31
129	Increasing Incidence of Invasive Aspergillosis in Pediatric Hematology Oncology Patients Over the Last Decade. <i>Journal of Pediatric Hematology/Oncology</i> , 2009, 31, 642-646.	0.3	54
130	Dyspnea as the first manifestation of primary pancreatic lymphoma. <i>Pediatric Blood and Cancer</i> , 2008, 50, 434-434.	0.8	4
131	Unrelated cord blood transplantation for severe combined immunodeficiency and other primary immunodeficiencies. <i>Bone Marrow Transplantation</i> , 2008, 41, 627-633.	1.3	30
132	<i>Aspergillus</i> of the bladder after hematopoietic transplantation in a pediatric patient: Successful treatment with intravesical voriconazole and surgery. <i>Pediatric Transplantation</i> , 2008, 12, 242-245.	0.5	12
133	Primary gastrointestinal aspergillosis after autologous peripheral blood progenitor cell transplantation: an unusual presentation of invasive aspergillosis. <i>Transplant Infectious Disease</i> , 2008, 10, 193-196.	0.7	19
134	Intentional induction of mixed haematopoietic chimerism as platform for cellular therapy after HLAâ€“matched allogeneic stem cell transplantation in childhood leukaemia patients. <i>British Journal of Haematology</i> , 2008, 140, 340-343.	1.2	10
135	ALLOGENEIC HEMOPOIETIC STEM CELL TRANSPLANTATION FOR CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA IN SECOND COMPLETE REMISSIONâ€“Similar Outcomes After Matched Related and Unrelated Donor Transplant: A Study of the Spanish Working Party for Blood and Marrow Transplantation in Children (Getmon). <i>Pediatric Hematology and Oncology</i> , 2008, 25, 245-259.	0.3	11
136	Extracorporeal photochemotherapy for steroid-refractory graft-versus-host disease in low-weight pediatric patients. Immunomodulatory effects and clinical outcome. <i>Haematologica</i> , 2008, 93, 1278-1280.	1.7	26
137	Follow-up of healthy donors receiving granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization and collection. Results of the Spanish Donor Registry. <i>Haematologica</i> , 2008, 93, 735-740.	1.7	62
138	Mesenchymal Stem Cells are of Recipient Origin in Pediatric Transplantations Using Umbilical Cord Blood, Peripheral Blood, or Bone Marrow. <i>Journal of Pediatric Hematology/Oncology</i> , 2007, 29, 388-392.	0.3	17
139	PBSC collection in extremely low weight infants: a single-center experience. <i>Cytotherapy</i> , 2007, 9, 356-361.	0.3	11
140	Extramedullary acute lymphoblastic leukaemia in childhood. <i>European Journal of Haematology</i> , 2007, 79, 182-182.	1.1	0
141	Risk Score for Pediatric Intensive Care Unit Admission in Children Undergoing Hematopoietic Stem Cell Transplantation and Analysis of Predictive Factors for Survival. <i>Journal of Pediatric Hematology/Oncology</i> , 2005, 27, 526-531.	0.3	31
142	Hematopoietic transplantation for bone marrow failure syndromes and thalassemia. <i>Bone Marrow Transplantation</i> , 2005, 35, S17-S21.	1.3	11
143	Long-term outcome of allogeneic or autologous haemopoietic cell transplantation for acute lymphoblastic leukaemia in second remission in children. GETMON experience 1983â€“1998. <i>Bone Marrow Transplantation</i> , 2005, 35, 895-901.	1.3	13
144	Long-term outcome of allogeneic PBSC transplantation in pediatric patients with hematological malignancies: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON) and the Spanish Group for Allogeneic Peripheral Blood Transplantation (GETH). <i>Bone Marrow Transplantation</i> , 2005, 36, 781-785.	1.3	23

#	ARTICLE	IF	CITATIONS
145	Full donor chimerism by day 30 after allogeneic peripheral blood progenitor cell transplantation is associated with a low risk of relapse in pediatric patients with hematological malignancies. <i>Leukemia</i> , 2005, 19, 504-506.	3.3	24
146	High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors. <i>Journal of Neuro-Oncology</i> , 2005, 71, 33-38.	1.4	80
147	Hematopoietic stem cell transplantation using umbilical cord blood progenitors: review of current clinical results. <i>Bone Marrow Transplantation</i> , 2004, 33, 675-690.	1.3	71
148	Risk assessment and outcome of chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell transplantation in pediatric patients. <i>Bone Marrow Transplantation</i> , 2004, 34, 433-438.	1.3	10
149	Engraftment syndrome after autologous peripheral blood progenitor cell transplantation in pediatric patients: a prospective evaluation of risk factors and outcome. <i>Bone Marrow Transplantation</i> , 2004, 34, 1051-1055.	1.3	20
150	A prospective randomized study of clinical and economic consequences of using G-CSF following autologous peripheral blood progenitor cell (PBPC) transplantation in children. <i>Bone Marrow Transplantation</i> , 2004, 34, 1077-1081.	1.3	14
151	High-dose Chemotherapy With Autologous Stem Cell Rescue as First Line of Treatment in Young Children with Medulloblastoma and Supratentorial Primitive Neuroectodermal Tumors. <i>Journal of Neuro-Oncology</i> , 2004, 67, 101-106.	1.4	30
152	Risks and methods for peripheral blood progenitor cell collection in small children. <i>Transfusion and Apheresis Science</i> , 2004, 31, 221-231.	0.5	14
153	Fatal Hepatic Failure Secondary to Acute Herpes Simplex Virus Infection. <i>Journal of Pediatric Hematology/Oncology</i> , 2004, 26, 686-688.	0.3	21
154	Engraftment Syndrome Emerges as the Main Cause of Transplant-Related Mortality in Pediatric Patients Receiving Autologous Peripheral Blood Progenitor Cell Transplantation. <i>Journal of Pediatric Hematology/Oncology</i> , 2004, 26, 492-496.	0.3	15
155	Successful Treatment of Invasive Aspergillosis With Oral Voriconazole Following Intravenous Liposomal Amphotericin in a Child With Acute Lymphoblastic Leukemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2004, 26, 117-119.	0.3	5
156	Chemotherapy-Related Secondary Acute Myeloid Leukemia in Patients Diagnosed With Osteosarcoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2004, 26, 454-456.	0.3	12
157	Heparin based anticoagulation during peripheral blood stem cell collection may increase the CD34+ cell yield. <i>Haematologica</i> , 2004, 89, 249-51.	1.7	14
158	Cerebral toxoplasmosis following etanercept treatment for idiopathic pneumonia syndrome after autologous peripheral blood progenitor cell transplantation (PBPCT). <i>Annals of Hematology</i> , 2003, 82, 649-653.	0.8	32
159	Transplantation of marrow cells from children with standard risk-acute lymphoblastic leukemia at the end of therapy into NOD/SCID mice for detecting residual leukemic cells with in vivo growth potential. <i>Leukemia Research</i> , 2003, 27, 1153-1157.	0.4	3
160	Large volume leukapheresis in small children: safety profile and variables affecting peripheral blood progenitor cell collection. <i>Bone Marrow Transplantation</i> , 2003, 31, 263-267.	1.3	24
161	Factors predicting peripheral blood progenitor cell collection from pediatric donors for allogeneic transplantation. <i>Haematologica</i> , 2003, 88, 919-22.	1.7	25
162	Second Mobilization and Collection of Peripheral Blood Progenitor Cells in Healthy Donors Is Associated with Lower CD34+Cell Yields. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2002, 11, 705-709.	1.8	16

#	ARTICLE	IF	CITATIONS
163	Peripheral Blood Progenitor Cell Collection in Low-Weight Children. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2002, 11, 633-642.	1.8	13
164	Analysis of factors associated with low peripheral blood progenitor cell collection in normal donors. <i>Transfusion</i> , 2002, 42, 4-9.	0.8	87
165	Loss of heterozygosity of p16 correlates with minimal residual disease at the end of the induction therapy in non-high risk childhood B-cell precursor acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2002, 26, 817-820.	0.4	10
166	Matched-pair analysis comparing allogeneic PBPC and BMT from HLA-identical relatives in childhood acute lymphoblastic leukemia. <i>Bone Marrow Transplantation</i> , 2002, 30, 9-13.	1.3	13
167	Engraftment syndrome in children undergoing autologous peripheral blood progenitor cell transplantation. <i>Bone Marrow Transplantation</i> , 2002, 30, 355-358.	1.3	27
168	Granulocyte colony-stimulating factor alone at 12 μ g/kg twice a day for 4 days for peripheral blood progenitor cell priming in pediatric patients. <i>Bone Marrow Transplantation</i> , 2002, 30, 417-420.	1.3	30
169	Predicting factors for admission to an intensive care unit and clinical outcome in pediatric patients receiving hematopoietic stem cell transplantation. <i>Haematologica</i> , 2002, 87, 292-8.	1.7	41
170	"Pseudotumor cerebri" following allogeneic bone marrow transplantation (BMT). <i>Annals of Hematology</i> , 2001, 80, 236-237.	0.8	18
171	Favourable effect of the combination of acute and chronic graft-versus-host disease on the outcome of allogeneic peripheral blood stem cell transplantation for advanced haematological malignancies. <i>British Journal of Haematology</i> , 2001, 114, 544-550.	1.2	23
172	Donor age-related differences in PBPC mobilization with rHuG-CSF. <i>Transfusion</i> , 2001, 41, 201-205.	0.8	50
173	Acute autoimmune hemolytic anemia following unrelated cord blood transplantation as an early manifestation of chronic graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2001, 28, 89-92.	1.3	26
174	Allogeneic peripheral blood stem cell transplantation (PBSCT) from HLA-identical sibling donors in children with hematological diseases: a single center pilot study. <i>Bone Marrow Transplantation</i> , 2001, 28, 537-543.	1.3	11
175	Ki-1+ANAPLASTIC LARGE CELL LYMPHOMA IN A CHILD WITH UNPREDICTABLE CLINICAL COURSE. <i>Pediatric Hematology and Oncology</i> , 2001, 18, 143-146.	0.3	2
176	Long-Term Hematopoietic Engraftment after Autologous Peripheral Blood Progenitor Cell Transplantation in Pediatric Patients: Effect of the CD34+ Cell Dose. <i>Vox Sanguinis</i> , 2000, 79, 145-150.	0.7	18
177	Using peripheral blood progenitor cells (PBPC) for transplantation in pediatric patients: a state-of-the-art review. <i>Bone Marrow Transplantation</i> , 2000, 26, 1291-1298.	1.3	26
178	Autologous stem cell transplantation for advanced Hodgkin's disease in children. <i>Bone Marrow Transplantation</i> , 2000, 25, 31-34.	1.3	28
179	High Survival Rate in Infant Acute Leukemia Treated With Early High-Dose Chemotherapy and Stem-Cell Support. <i>Journal of Clinical Oncology</i> , 2000, 18, 3256-3261.	0.8	34
180	SHORT-TERM FOLLOW-UP OF THE NUTRITIONAL STATUS OF CHILDREN UNDERGOING AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION. <i>Pediatric Hematology and Oncology</i> , 2000, 17, 559-566.	0.3	10

#	ARTICLE	IF	CITATIONS
181	Peripheral blood progenitor cell (PBPC) collection by large-volume leukapheresis from pediatric donors. Bone Marrow Transplantation, 1999, 23, 631-632.	1.3	9
182	An uncommon case of late thrombotic thrombocytopenic purpura (42 months) after autologous peripheral blood stem cell (PBSC) transplantation in a child. Bone Marrow Transplantation, 1999, 23, 735-736.	1.3	1
183	G-CSF-mobilized PBSCT in children with AML in first complete remission. Bone Marrow Transplantation, 1999, 23, 975-976.	1.3	1
184	Administration of recombinant human granulocyte colony-stimulating factor to normal donors: results of the Spanish National Donor Registry. Bone Marrow Transplantation, 1999, 24, 723-728.	1.3	49
185	High-dose busulfan/melphalan as conditioning for autologous PBPC transplantation in pediatric patients with solid tumors. Bone Marrow Transplantation, 1999, 24, 1157-1159.	1.3	46
186	SUCCESSFUL UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION IN A CHILD WITH OMENN'S SYNDROME. Pediatric Hematology and Oncology, 1999, 16, 361-366.	0.3	13
187	Megatherapy in children with high-risk Ewing's sarcoma in first complete remission. Bone Marrow Transplantation, 1998, 21, 795-799.	1.3	29
188	Progenitor cell subsets and engraftment kinetics in children undergoing autologous peripheral blood stem cell transplantation. British Journal of Haematology, 1998, 101, 104-110.	1.2	28
189	CNS Sequelae in Langerhans Cell Histiocytosis: Progressive Spinocerebellar Degeneration as a Late Manifestation of the Disease. Pediatric Hematology and Oncology, 1997, 14, 577-584.	0.3	12
190	Non-tunneled catheters for the collection and transplantation of peripheral blood stem cells in children. Bone Marrow Transplantation, 1997, 20, 53-56.	1.3	21
191	Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone. Bone Marrow Transplantation, 1997, 20, 211-217.	1.3	121
192	Clinical relevance of T-cell receptor delta gene rearrangements in childhood B-precursor cell acute lymphoblastic leukaemia. British Journal of Haematology, 1997, 99, 308-313.	1.2	5
193	COLLECTION AND TRANSPLANTATION OF PERIPHERAL BLOOD PROGENITOR CELLS MOBILIZED BY G-CSF ALONE IN CHILDREN WITH MALIGNANCIES. British Journal of Haematology, 1996, 94, 148-154.	1.2	47
194	A Unique Dysembryonic Neoplasm of the Adrenal Gland Composed of Nephrogenic Rests in a Child. American Journal of Surgical Pathology, 1996, 20, 118-124.	2.1	9
195	Complicated Pulmonary Aspergillosis with Pneumothorax and Pneumopericardium in a Child with Acute Lymphoblastic Leukemia. Pediatric Hematology and Oncology, 1995, 12, 195-199.	0.3	14
196	T-Cell Depleted Haploidentical Transplantation in Children With Hematological Malignancies: A Comparison Between CD3+/CD19+ and TCR α 1 β 2+/CD19+ Depletion Platforms. Frontiers in Oncology, 0, 12, .	1.3	1